Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder
Links shared publicly online about this topic.
- 47total visits
Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder
Lightlake Therapeutics Inc., an early stage biopharmaceutical company currently developing a nasal spray for the treatment of overweight and obese patients with Binge Eating Disorder, today announced that its patient testing stage of the Phase II clinical trials will start August 26th, 2011
View full resource at news-medical.net
Tags: Obesity, Eating Disorder, Binge Eating, Nose, Disease and Condition, Clinical Trial, Opiate
Most Recently Shared on August 25, 2011 at 6:30 am By:
Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder: Lightlake The... http://t.co/9gQuyJ5
Advertisement
